Aristotle life summary

aristotle life summary

Aristotle, internet Encyclopedia of Philosophy

Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts healthy volunteers: no criteria inclusion Criteria: Males and females 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke: Age 75, previous stroke transient. Please refer to this study by its ClinicalTrials. Gov identifier (nct number nct00412984 Sponsors and Collaborators Bristol-myers Squibb Investigators Study director: Bristol-myers Squibb Bristol-myers Squibb More Information Additional Information: Publications automatically indexed to this study by ClinicalTrials. Gov identifier (nct number Sharma a, hijazi z, andersson u, al-Khatib sm, lopes rd, alexander jh, held c, hylek em, leonardi s, hanna m, ezekowitz ja, siegbahn a, granger cb, wallentin. The Use of biomarkers to Predict Specific causes of death in Patients with Atrial Fibrillation: Insights from the aristotle trial. Doi: Epub ahead of print Pol t, held c, westerbergh j, lindbäck j, alexander jh, alings m, erol c, goto s, halvorsen s, huber k, hanna m, lopes rd, ruzyllo w, granger cb, hijazi.

Aristotle 's, ethics stanford Encyclopedia of Philosophy )

Ratenumber of mtf adjudicated timi bleeding events per 100 patient years. Timi bleeding Criteria: Major bleedingIntracranial bleeding and/or clinically overt bleeding associated with 5 gm/dL fall in Hgb or 15 fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleedingClinically overt bleeding associated with 3 gm/dL fall in Hgb or a 10 fall in Hct from baseline, accounting for transfusions. Number of Participants With Net-Clinical Benefit During Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Net-Clinical Benefit composite of stroke, systemic embolism and isth major bleeding. Rate of Net-Clinical Benefit During Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Ratenumber of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit composite of stroke, systemic embolism and isth major bleeding Eligibility Criteria information from the national Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn About Clinical Studies.

Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of bsd. Discontinuations due to ae: all saes or AEs with onset from first dose of bsd and with action takendrug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of bsd. Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (gusto) During the Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Ratenumber of adjudicated gusto bleeding events per 100 patient years. Gusto bleeding Criteria: gusto severe (or life -threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. Gusto moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in myocardial Infarction (timi) During the Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug.

aristotle life summary

Metaphysics aristotle ), wikipedia

Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical events Committee determines is the primary cause of death or contributes directly to death. Rate of All Bleeding events During Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days paper after the last dose of blinded study drug. Ratenumber of all bleeding events per 100 patient years. "All bleeding events" include major bleeding, crnm bleeding (see outcome measure 12 Description for definitions plus events of minor bleeding and fatal bleeding. Other Outcome measures: Number of Participants With Adverse events (AEs Bleeding AEs, serious Adverse events (SAEs discontinuations revelation due to aes, or deaths During the Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose. AE: all saes or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). Sae: all saes with onset from first dose through 30 days after the last dose of bsd.

Major bleedingbleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led. Crnm bleedingbleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic. Rate of events of Major or Clinically relevant Non-Major (crnm) Bleed During Treatment Period  Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Ratenumber of major or crnm bleed events per 100 patient years. Majorclinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. Crnm bleedingclinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. Number of Participants With All Bleeding events During Treatment Period  Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. All bleeding events include major bleeding, crnm bleeding (see outcome measure 12 Description for definitions plus events of minor bleeding and fatal bleeding.

Aristotle and Happiness - the pursuit of Happiness

aristotle life summary

Aristotle - ancient History

Cardiovasculardeaths due to ischemic and hemorrhagic stroke, se, mi, sudden death, heart failure, other cardiovascular, and unobserved deaths. Rate of Ischemic or Unspecified Stroke, hemorrhagic Stroke, systemic Embolism (se and myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected. diagnosis for an acute or evolving mielevation of creatine kinase-mb isoenzyme (ck-mb) or Troponin t or i 2 the upper limit of normal (uln or if no ck-mb or troponin values are available, a total ck 2uln, or new, significant (0.04 s) Q waves. For descriptions of Stroke and se, see outcome measure. Rate of Ischemic or Unspecified Stroke, hemorrhagic Stroke, systemic Embolism (se myocardial Infarction (MI) and All-cause death (ACD) (as Composite Endpoints) During the Intended Treatment Period Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which. diagnosis for an acute or evolving mielevation of ck-mb or Troponin t or i 2 the uln, or if no ck-mb or troponin values are available, a total ck 2uln, or new, significant (0.04 s) Q waves in 2 contiguous leads.

For description of acd, see outcome measure. Number of Warfarin/Vitamin k antagonist (VKA) naive participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected. For description of Major bleeding, see outcome measure. Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin k antagonist (VKA) naive participants During the Intended Treatment Period Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that. Number of Participants With events of Major or Clinically relevant Nonmajor (crnm) Bleed During Treatment Period Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug.

Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period  Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events 448 would. RateNumber of adjudicated stroke or se events per 100 patient years. Secondary outcome measures : Number of Participants With event of Major (International Society on Thrombosis and Hemostasis isth) Bleeding During Treatment Period  Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was.7 years in each treatment group. . isth bleeding Criteria: Major bleedinga bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least.


Rate of Adjudicated Major (isth) Bleed events During Treatment Period  Time Frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Ratenumber of adjudicated major (isth) bleed events per 100 patient years. Isth bleeding Criteria: Major bleedinga bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least. Number of Participants With events of All-cause death During the Intended Treatment Period  Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events 448 would. death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovasculardeaths due to ischemic and hemorrhagic stroke, se, myocardial infarction (mi sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascularall deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). Rate of Adjudicated All-cause death During the Intended Treatment Period  Time Frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events 448 would have occurred; set.

Internet Encyclopedia of Philosophy

Atrial Fibrillation Atrial Flutter, drug: warfarin Drug: night apixaban, phase. Study design, study type : Interventional (Clinical Trial actual Enrollment : 20976 participants, allocation: Randomized. Intervention Model: Parallel Assignment, masking: double (Participant, Investigator primary purpose: Prevention, official Title: a phase 3, Active (Warfarin) Controlled, randomized, double-Blind, parallel Arm Study to evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation. Actual Study Start Date : December 31, 2006, actual Primary completion Date : may 25, 2011, actual Study completion Date : may 25, 2011, arms and Interventions, active comparator: 1, drug: warfarin. Oral tablets,.0 mg, adjusted to an inr.5 (range.0.0). Other Names: coumadin bms-565793 Experimental: 2 Drug: apixaban Oral tablets,.0 mg.5 mg, twice daily Other Name: bms-562247 Outcome measures Primary outcome measures : Number of Participants With First event of Ischemic/Unspecified Stroke, hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment. All suspected efficacy events were adjudicated by the central events Committee (CEC). Diagnosis of strokethe nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SEclinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.

aristotle life summary

Despite the risks, we need to develop superintelligence promptly if we are to have any chance of surviving. Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation - full Text view - clinicalTrials. Glossary, study record managers: refer to the. Data Element Definitions if submitting registration or results information. Search for terms x, skip to main Content, save this study, the safety and engineer scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the. Read our disclaimer for details. Sponsor: Bristol-myers Squibb, information provided by (Responsible party bristol-myers Squibb, study description, brief. Summary : The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

or Accelerated? It is hard to think of any problem that a superintelligence could not either solve or at least help us solve. Disease, poverty, environmental destruction, unnecessary suffering of all kinds: these are things that a superintelligence equipped with advanced nanotechnology would be capable of eliminating. Additionally, a superintelligence could give us indefinite lifespan, either by stopping and reversing the aging process. Given this promise, and considering Bs claim that si will probably be developed anyway, we might as well do this asap. If we get to superintelligence first, we may avoid this risk from nanotechnology and many others. If, on the other hand, we get nanotechnology first, we will have to face both the risks from nanotechnology and, if these risks are survived, also the risks from superintelligence. Reflection i have made my views on this clear many times.

He is currently Professor, faculty of Philosophy oxford Martin School; Director, future of Humanity Institute; and Director, Program on the Impacts of Future technology; all at Oxford University. His recent book, superintelligence: Paths, dangers, Strategies, is the definitive work on superintelligence. A few of its main issues were discussed in his previous article, Ethical Issues in Advanced. Here is a brief outline of that article. Introduction a superintelligence is any intellect that vastly outperforms the best human brains in practically every field, including scientific creativity, general wisdom, and social skills. . This definition leaves open how the superintelligence is implemented it could be in a digital computer, an ensemble of networked computers, cultured cortical tissue, or something else. B states that there is no reason to believe we wont have si in the lifetime of some persons alive today. Superintelligence business (SI) is different And in ways, we cant even imagine.

SparkNotes : Aristotle : Ethics and Politics

Unfortunately, our website is currently unavailable in most European countries. We are engaged on the issue and committed to looking at options that support our full range of digital offerings to the eu market. We continue to identify technical compliance solutions that will provide all readers with our award-winning journalism. Nick bostrom (1973 ) holds. From the london School of Economics (2000). He apple is a co-founder of the world Transhumanist Association (now called Humanity) and co-founder of the Institute for Ethics and Emerging Technologies. He was on the faculty of Yale University until 2005, when he was appointed Director of the newly created Future of Humanity Institute at Oxford University.


Aristotle life summary
all articles 43 articles
These are words youll find in a ( bad ). How much time are you willing to spend commuting?

4 Comment

  1. Device - he begins writin g The outsiders as an English class assignment. Best PowerPoint presentations: 50 inspiring slide decks that teach you things ( about design, copy, sales, innovation and much more). In Issue 13 of, taking, sides, the controversial question have antidepressant Drugs Proven to be Effective. Fantastic glass paperweights were initially mainstream somewhere around 18 in focal France. Edited by the horror Writers Association (hwa a worldwide. Most people due to stress at work have health problems.

  2. In an ielts both sides and opinion essay you need to discuss each side of an argument using the third person (people believe). We ask a celebrity a set of devilishly probing questions and only accept the definitive answer. i dont really want a candidate to tell me they are willing to learn when the profile just doesnt cover the basic job requirements. Automatic works cited and bibliography formatting for mla, apa and Chicago/Turabian citation styles. Brought The, outsiders adaptation to theaters, featuring a cast that included many rising stars. To help candidates draft such a resume, below we have provided a collection of service resume examples for various positions which may exist in the service sector.

  3. It s always been bad writing. With the common Core Standards. Happiness is the meaning and the purpose of life, the whole aim and end of human existence. The ancient Greek philosopher. Aristotle said these words more than 2,000 years ago, and they still ring true today. Happiness is a broad term that describes the experience of positive emotions, such.

  4. (This post is my summary of a chapter in a book i often used in university classes: Twelve theories of Human Nature, by Stevenson, haberman, and Wright, Oxford Univ. Press.) jean-paul Sartre ( ) was Frances most important philosopher for much of the twentieth-century as well. Part I: Introduction-What inspired my argumentative response? For decades, too many high-school teachers have been instilling persuasive writing skills by teaching students the five-paragraph essay. You know it: It s bad writing.

  5. This side provides useful and practical guidance for making efficient and effective decisions in both public and private life. Nick bostrom (1973 ) holds. From the london School of Economics (2000). He is a co-founder of the world Transhumanist Association (now called Humanity) and co-founder of the Institute for Ethics and Emerging Technologies. He was on the faculty of Yale University until 2005, when he was.

  6. What louis Pasteur and the others who denied spontaneous generation demonstrated is that life does not currently spontaneously arise in complex form from nonlife in nature; he did not demonstrate the impossibility of life arising in simple form from nonlife by way of a long. Aristotle and Dante discover the secrets of the Universe has 155,120 ratings and 23,600 reviews. Thomas said: 3 steps to become me, thomas:1. Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (. Decisions are the heart of success and at times there are critical moments when they can be difficult, perplexing and nerve racking.

Leave a reply

Your e-mail address will not be published.


*